Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries

Baseline rilpivirine drug resistance mutations (DRMs) are a risk factor for virological failure in patients treated with long-acting cabotegravir and rilpivirine (CAB/RPV LA). We investigated rilpivirine cross-resistance in treatment-naive and experienced patients in South Africa. One in 10 treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Steegen, Kim, Chandiwana, Nomathemba, Sokhela, Simiso, Venter, Willem D.F., Hans, Lucia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090297/
https://www.ncbi.nlm.nih.gov/pubmed/36779485
http://dx.doi.org/10.1097/QAD.0000000000003505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090297/
https://www.ncbi.nlm.nih.gov/pubmed/36779485
http://dx.doi.org/10.1097/QAD.0000000000003505

Ejemplares similares